HER2 Cancer Therapy

Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy

Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...

By cGxPwire Editor
May 23, 2026

.Clinical

SystImmune and BMS Advance iza-bren for Difficult-to-Treat Tumors

Redmond, Washington, USA – May 21, 2026 SystImmune, Inc. announced that multiple clinical and late-stage development data sets from...

By cGxPwire Editor
May 23, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

HER2 Cancer Therapy

Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy

SystImmune and BMS Advance iza-bren for Difficult-to-Treat Tumors